A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva®)

Márquez, Gemma; Herrera‐Acosta, Enrique; Vidal, Isabel; Galvany, Loida; Iglesias, Maribel; Umbert, Pablo

doi:10.1111/j.1365-4632.2009.03752.x

Cited by 15 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most prevalent side effects were rash and diarrhea 37 ; others included mucositis, headache, and hyperbilirubinemia. 38 Ocular side effects included trichomegaly leading to corneal ulcer, 39,40 conjunctivitis, and ectropion with epiphora. 41 …”

Section: Resultsmentioning

confidence: 99%

Targeted Therapy for Orbital and Periocular Basal Cell Carcinoma and Squamous Cell Carcinoma

Yin

Pfeiffer

Esmaeli

2013

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Purpose To review the literature on targeted therapy for orbital and periocular basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) and provide examples of patients recently treated with such therapy. Methods We reviewed the literature on clinical results of targeted therapy and the molecular basis for targeted therapy in orbital and periocular BCC and cutaneous SCC. We also present representative cases from our practice. Results Mutation in the patched gene (PTCH1) has been implicated in BCC, and overexpression of epidermal growth factor receptor (EGFR) has been shown in SCC. Vismodegib, an inhibitor of smoothened, which is activated upon binding of hedgehog to Ptc, has been shown to significantly decrease BCC tumor size or even produce complete resolution, especially in cases of basal cell nevus syndrome. Similarly, EGFR inhibitors have been shown to significantly decrease SCC tumor size in cases of locally advanced and metastatic disease. We describe successful outcomes after vismodegib treatment in a patient with basal cell nevus syndrome with numerous bulky lesions of the eyelid and periocular region and erlotinib (EGFR inhibitor) treatment in a patient with SCC who was deemed not to be a good surgical candidate because of advanced SCC of the orbit with metastasis to the regional lymph nodes, advanced age, and multiple medical comorbidities. Conclusion Targeted therapy using hedgehog pathway and EGFR inhibitors shows significant promise in treatment of orbital and periocular BCC and cutaneous SCC, respectively. Such targeted therapy may be appropriate for patients who are not good candidates for surgery.

show abstract

Section: Resultsmentioning

confidence: 99%

Targeted Therapy for Orbital and Periocular Basal Cell Carcinoma and Squamous Cell Carcinoma

Yin

Pfeiffer

Esmaeli

2013

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…[9,18] EGFR antagonists are of two types: monoclonal antibodies and small molecule inhibitors. [1][2][3][4][5][6]9,11,[13][14][15][16][17] An acneiform papulopustular follicular reaction is common and the frequency of development of this pustular eruption appears to be dose dependent. They include cetuximab, matuzumab, nimotuzumab, and panitumumab.…”

Section: Discussionmentioning

confidence: 99%

“…[8,12,15,16,19] Mucocutaneous reactions to EGFR inhibitors are summarized in table I. [1][2][3][4][5][6]9,11,14,15,17,19,20,[22][23][24][25][26][27][28][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] These include not only increased (hypertrichosis) and decreased (alopecia) Acral fissures Fissures occur on the hands and feet, fingers (tips and interphalangeal joints), and toes. [8,15,26] Indeed, the papulopustular eruption has been associated with favorable tumor response, lengthening of time to progression, and improved overall survival.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cetuximab-Associated Elongation of the Eyelashes

Cohen

Escudier

Kurzrock

2011

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Eyelash trichomegaly is an uncommon drug-associated sequelae experienced during treatment with epidermal growth factor receptor (EGFR) inhibitors. Elongation of the eyelashes induced by these agents has predominantly been observed in oncology patients with either colorectal or lung cancer. It is most frequently associated with cetuximab and erlotinib; however, it has also been described in individuals treated with gefitinib or panitumumab. We describe cetuximab-associated eyelash trichomegaly in a woman with metastatic rectal carcinoma. We review the clinical presentation, adverse effects, and management of EGFR inhibitor-related eyelash trichomegaly. The long eyelashes are not a drug-limiting adverse effect and some patients consider the change to be cosmetically enhancing. Trimming the lashes with scissors can usually ameliorate local symptoms. The eyelashes often return to their original length at variable time periods after EGFR inhibitor therapy is discontinued.

show abstract

“…Known ocular side effects are ocular surface disorders, conjunctivitis, trichomegaly and keratoconjunctivitis 2–4. The drug is reported to be associated with trichomegaly and corneal epithelial defects.…”

Section: Discussionmentioning

confidence: 99%

Erlotinib-related bilateral anterior uveitis

Ali

Kumar²,

Usman-Saeed³

et al. 2011

Case Reports

View full text Add to dashboard Cite

The authors report the case of a 68-year-old woman with secondary adenocarcinoma of the lungs from an unknown primary. Erlotinib was started which produced symptoms suggestive of uveitis. Erlotinib was stopped and restarted a month later at a lower dose, which resulted in severe bilateral anterior uveitis. The uveitis settled after stopping erlotinib and treatment with topical steroids and cycloplegics. To the best of the authors' knowledge, this is the first case of erlotinib-related anterior uveitis.

show abstract

A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva®)

Cited by 15 publications

References 6 publications

Targeted Therapy for Orbital and Periocular Basal Cell Carcinoma and Squamous Cell Carcinoma

Targeted Therapy for Orbital and Periocular Basal Cell Carcinoma and Squamous Cell Carcinoma

Cetuximab-Associated Elongation of the Eyelashes

Erlotinib-related bilateral anterior uveitis

Contact Info

Product

Resources

About